Breaking News Instant updates and real-time market news.

AKCA

Akcea Therapeutics

$34.33

0.64 (1.90%)

16:27
08/06/18
08/06
16:27
08/06/18
16:27

Akcea Therapeutics reports Q2 EPS (72c), consensus ($1.24)

Reports Q2 revenue $18.3M, consensus $12.56M. "This is an incredibly exciting time for Akcea with TEGSEDI now approved in Europe and upcoming PDUFA dates in the US for WAYLIVRAand TEGSEDI. We are ready to launch TEGSEDI first in Germany post the summer holidays, and in the US, we are prepared to launch both products quickly upon approval. We are poised to deliver these drugs to two underserved, rare disease patient communities in our three initial key regions. We've also accelerated global access to TEGSEDI and WAYLIVRA in Latin America through our partnership with PTC Therapeutics," said Paula Soteropoulos, chief executive officer of Akcea. "In addition, with the upcoming top line results from the AKCEA-APO(a)-LRx Phase 2 study, we have the potential to make a significant step forward for patients with cardiovascular disease caused by elevated levels of lipoprotein a, or Lp(a). With the largest efficacy, safety and treatment duration database to date, these results could be a game changer for the ligand conjugated antisense, or LICA, technology platform and we look forward to sharing them later this year."

  • 06

    Aug

  • 30

    Aug

  • 06

    Oct

AKCA Akcea Therapeutics
$34.33

0.64 (1.90%)

05/11/18
WELS
05/11/18
UPGRADE
WELS
Outperform
Akcea Therapeutics upgraded to Outperform from Market Perform at Wells Fargo
05/11/18
STFL
05/11/18
NO CHANGE
Target $25
STFL
Hold
Akcea clarity improved by panel vote, but challenges remain, says Stifel
Stifel analyst Stephen Willey said the FDA Advisory Committee's vote in favor of supporting the approval of volanesorsen improves the regulatory clarity for Akcea Therapeutics, but he believes commentary from both voting members and FDA reviewers would suggest there's still "tangible risk" to the formal FDA decision due on August 30. He has reduced his peak worldwide sales estimates to approximately $200M in an effort to better reflect the high proportion of patient discontinuations and dose-reductions occurring within clinical development, which lowered his price target on Akcea shares to $25 from $30. Willey keeps a Hold rating on the stock.
05/11/18
WELS
05/11/18
UPGRADE
Target $33
WELS
Outperform
Akcea upgraded to Outperform with $33 target at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded Akcea Therapeutics to Outperform from Market Perform after an FDA panel voted 12-8 to support approval of Waylivra for the treatment of people with familial chylomicronemia syndrome. The analyst expects the vote to support approval of the drug by the August 30 action date. He raised his price target for Akcea shares to $33 from $30.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $50
PIPR
Neutral
Ionis approval narrower than expected, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says the European approval of Tegsedi announced this morning Ionis Pharmaceuticals (IONS) and Akcea Therapeutics (AKCA) for the treatment of stage 1 or stage 2 polyneuropoathy in adult patients with hATTR was narrower than he originally expected. The indication is narrower than the broader hATTR patient population, inclusive of both cardiomyopathy and polyneuropathy, but makes sense considering that the pivotal trial primarily enrolled patients with stage 1 and 2 polyneuropathy, Van Buren tells investors in a research note. The analyst adds that while the approval is a positive development and Tegsedi represents the largest near-term pipeline opportunity for Ionis, he wants to observe positive early launch metrics and confirmation of the opportunity before getting more constructive on the shares. He keeps a Neutral rating on Ionis with a $50 price target.

TODAY'S FREE FLY STORIES

ATTO

Atento

$3.95

0.06 (1.54%)

20:51
03/19/19
03/19
20:51
03/19/19
20:51
Earnings
Atento reports Q4 recurring EPS 21c, consensus 17c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

TRHC

Tabula Rasa HealthCare

$60.28

1.35 (2.29%)

20:47
03/19/19
03/19
20:47
03/19/19
20:47
Recommendations
Tabula Rasa HealthCare analyst commentary at Piper Jaffray »

Tabula Rasa HealthCare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

GIS

General Mills

$47.24

-0.365 (-0.77%)

20:25
03/19/19
03/19
20:25
03/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

TRN

Trinity Industries

$22.46

-0.25 (-1.10%)

20:20
03/19/19
03/19
20:20
03/19/19
20:20
Hot Stocks
Trinity Industries names Leldon Echols chairman of the board »

Trinity Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

TIGR

UP Fintech

$0.00

(0.00%)

20:06
03/19/19
03/19
20:06
03/19/19
20:06
Syndicate
UP Fintech 13M share IPO priced at $8.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

SND

Smart Sand

$4.27

-0.4 (-8.57%)

20:01
03/19/19
03/19
20:01
03/19/19
20:01
Initiation
Smart Sand initiated at B. Riley FBR »

Smart Sand initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYFT

Lyft

$0.00

(0.00%)

20:00
03/19/19
03/19
20:00
03/19/19
20:00
Initiation
Lyft initiated at DA Davidson »

Lyft initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

DERM

Dermira

$14.13

1.52 (12.05%)

19:40
03/19/19
03/19
19:40
03/19/19
19:40
Syndicate
Dermira 9.8M share Secondary priced at $13.25 per share »

Citi, Cowen, Cantor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

NVRO

Nevro

$44.76

0.37 (0.83%)

19:38
03/19/19
03/19
19:38
03/19/19
19:38
Upgrade
Nevro rating change at BMO Capital »

Nevro upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

TORC

ResTORbio

$7.16

-1.81 (-20.18%)

19:34
03/19/19
03/19
19:34
03/19/19
19:34
Syndicate
ResTORbio 7.2M share Secondary priced at $6.95 »

BofA/Merrill, SVB Leerink…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

NVRO

Nevro

$44.76

0.37 (0.83%)

19:33
03/19/19
03/19
19:33
03/19/19
19:33
Upgrade
Nevro rating change at BMO Capital »

Nevro upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

PFE

Pfizer

$42.32

0.51 (1.22%)

, MKGAY

Merck KGaA

$0.00

(0.00%)

19:17
03/19/19
03/19
19:17
03/19/19
19:17
Hot Stocks
Pfizer, Merck KGaA discontinue Phase III JAVELIN Ovarian PARP study »

Merck KGaA (MKGAY) and…

PFE

Pfizer

$42.32

0.51 (1.22%)

MKGAY

Merck KGaA

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 30

    Apr

  • 18

    May

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

, GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

19:11
03/19/19
03/19
19:11
03/19/19
19:11
Hot Stocks
Google outlines changes to Android mobile options, ad formats in Europe »

Google said in a blog…

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

, GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

19:08
03/19/19
03/19
19:08
03/19/19
19:08
Periodicals
Google offers Android, product ad concessions for Europe, WSJ says »

Google intends to ask all…

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

, SCS

Steelcase

$17.49

-0.115 (-0.65%)

19:06
03/19/19
03/19
19:06
03/19/19
19:06
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

SCS

Steelcase

$17.49

-0.115 (-0.65%)

AUPH

Aurinia Pharmaceuticals

$6.40

0.13 (2.07%)

NVRO

Nevro

$44.76

0.37 (0.83%)

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

TME

Tencent Music

$18.65

-0.48 (-2.51%)

WPRT

Westport

$1.50

(0.00%)

AIR

AAR Corp.

$35.10

(0.00%)

FDX

FedEx

$181.50

-0.92 (-0.50%)

FNV

Franco-Nevada

$75.64

0.035 (0.05%)

PRNB

Principia Biopharma

$36.88

0.48 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 01

    Apr

  • 02

    Apr

  • 05

    Apr

  • 14

    May

  • 28

    May

  • 24

    Jun

  • 26

    Jun

LGIH

LGI Homes

$54.89

-2.27 (-3.97%)

19:02
03/19/19
03/19
19:02
03/19/19
19:02
Hot Stocks
LGI Homes announces new community in Las Vegas »

LGI Homes, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

19:01
03/19/19
03/19
19:01
03/19/19
19:01
Hot Stocks
Sage says Zulresso approval represents 'game-changing approach' to PPD »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

QTRX

Quanterix

$24.59

-0.01 (-0.04%)

18:55
03/19/19
03/19
18:55
03/19/19
18:55
Syndicate
Breaking Syndicate news story on Quanterix »

Quanterix files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIHS

Senmiao Technology

$4.71

-0.275 (-5.52%)

18:55
03/19/19
03/19
18:55
03/19/19
18:55
Syndicate
Breaking Syndicate news story on Senmiao Technology »

Senmiao Technology files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$23.31

-0.23 (-0.98%)

18:54
03/19/19
03/19
18:54
03/19/19
18:54
Syndicate
Breaking Syndicate news story on Invitation Homes »

Invitation Homes files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

PULM

Pulmatrix

$1.70

-0.09 (-5.03%)

18:53
03/19/19
03/19
18:53
03/19/19
18:53
Syndicate
Breaking Syndicate news story on Pulmatrix »

Pulmatrix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

SIEN

Sientra

$8.81

-0.4 (-4.34%)

18:51
03/19/19
03/19
18:51
03/19/19
18:51
Recommendations
Sientra analyst commentary at Wells Fargo »

Sientra implied costs to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$23.31

-0.23 (-0.98%)

18:50
03/19/19
03/19
18:50
03/19/19
18:50
Syndicate
Breaking Syndicate news story on Invitation Homes »

Invitation Homes files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

FDX

FedEx

$181.50

-0.92 (-0.50%)

18:45
03/19/19
03/19
18:45
03/19/19
18:45
Hot Stocks
FedEx CEO: Domestic business is pretty good »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

LYFT

Lyft

$0.00

(0.00%)

18:41
03/19/19
03/19
18:41
03/19/19
18:41
Periodicals
Lyft IPO oversubscribed so far, Reuters reports »

Lyft's IPO is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.